Atea Pharmaceuticals, Inc.
BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTI- TUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
Last updated:
Abstract:
A compound of the structure: ##STR00001## or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
Status:
Application
Type:
Utility
Filling date:
3 May 2021
Issue date:
25 Aug 2022